Dual Epicardial and Endocardial Procedure (DEEP) for Persistent or Longstanding Persistent Atrial Fibrillation
Circulation: Arrhythmia and Electrophysiology · 2025
DOI: 10.1161/circep.125.013692 ↗Kurz gefasst
Klinische Studie in der Zeitschrift Circulation: Arrhythmia and Electrophysiology, 2025. Verfasst von Kenneth A Ellenbogen und 34 weiteren Autor:innen. Beteiligte Einrichtung: Divisions of Cardiology/Electrophysiology and Cardiac Surgery, Virginia Commonwealth University School of Medicine, Richmond (K.A.E., J.N.K., V.K.). Hauptthemen laut MEDLINE: Atrial Appendage, Atrial Fibrillation, Catheter Ablation, Endocardium. Die Arbeit nennt 41 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Despite advances in endocardial catheter ablation (ECA) for persistent atrial fibrillation (PersAF), undertreatment persists, especially in ECA nonresponders and in longstanding PersAF (LSPersAF), with disappointing ablation results. These patients need effective clinical treatment options. METHODS: The DEEP (Dual Epicardial and Endocardial Procedure) was a prospective, multicenter, single-arm, investigational device exemption trial to establish the safety and effectiveness of a combined epicardial/endocardial ablation procedure with left atrial appendage exclusion for PersAF/LSPersAF. Eligibility included age 18 to 75 years; symptomatic PersAF/LSPersAF refractory to ≥1 Class I/III antiarrhythmic drug; and ≤2 previous failed ECAs. Two-stage hybrid ablation included ECA performed at 91 to 121 days after the epicardial first stage (including left atrial appendage exclusion), followed by a 90-day blanking and 90-day antiarrhythmic drug optimization period. Primary effectiveness was defined as freedom from documented atrial fibrillation/atrial flutter/atrial tachycardia episodes >30 seconds through the 12-month follow-up, absent Class I/III antiarrhythmic drugs, except previously failed antiarrhythmic drugs at doses not exceeding those previously failed. Primary safety was defined as a composite of device/procedure-related serious adverse events within 30 days of epicardial ablation and 7 days of ECA. RESULTS: Ninety patients enrolled from February 2015 to December 2020; 83.3% (75/90) were male and mean±SD age was 63.4±7.7 years. AF classification was 83.3% (75/90) PersAF/16.7% (15/90) LSPersAF, and 47.8% (43/90) had prior ECA. The composite serious adverse events rate was 6.7% (6/90 [95% CI, 2.5%–13.9%]; P
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Divisions of Cardiology/Electrophysiology and Cardiac Surgery, Virginia Commonwealth University School of Medicine, Richmond (K.A.E., J.N.K., V.K.).
- MemorialCare Heart and Vascular Institute, Long Beach, CA (A.K., M.Y.L.).
- Cardiac Surgery Department, Universitair Ziekenhuis Brussel, Belgium (M.L.M., C.d.A.).
- Aspirus Wausau Hospital, WI (J.J., K.R.).
- University of Pittsburgh Medical Ctr (UPMC) Harrisburg, PA (M.M., M.G.L.).
- Amsterdam University Medical Center, Departments of Cardiology and Cardiothoracic Surgery, University of Amsterdam, the Netherlands (J.R.d.G., A.H.G.D.).
ORCID-Profile: Kenneth A Ellenbogen, Ali Khoynezhad, Mark La Meir, Carlo de Asmundis, Michael G Link, Joris R de Groot, Antoine H G Driessen, Mark Y Lee, Gansevoort Dunnington, Jonathan M Philpott, Thomas M Beaver, Junaid H Khan, Steven Kang, Gaurang D Gandhi, Eric J Okum, Nitish Badhwar, Tina Baykaner, Anson M Lee, Ken Frazier, Vigneshwar Kasirajan
Zitieren
APA
Ellenbogen, K. A., Khoynezhad, A., La Meir, M., de Asmundis, C., Koneru, J. N., Johnkoski, J., Rist, K., Mumtaz, M., Link, M. G., de Groot, J. R., Driessen, A. H. G., Lee, M. Y., Hoff, S. J., Bello, D., Dunnington, G., Eisenberg, S., Vloka, M., Taylor, B. J., Jones, S. D., …, & Kasirajan, V. (2025). Dual Epicardial and Endocardial Procedure (DEEP) for Persistent or Longstanding Persistent Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology. https://doi.org/10.1161/circep.125.013692
Vancouver
Ellenbogen KA, Khoynezhad A, La Meir M, de Asmundis C, Koneru JN, Johnkoski J, et al. Dual Epicardial and Endocardial Procedure (DEEP) for Persistent or Longstanding Persistent Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology. 2025. doi:10.1161/circep.125.013692
BibTeX
@article{Ellenbogen2025,
author = {Ellenbogen, Kenneth A and Khoynezhad, Ali and La Meir, Mark and de Asmundis, Carlo and Koneru, Jayanthi N and Johnkoski, John and Rist, Kevin and Mumtaz, Mubashir and Link, Michael G and de Groot, Joris R and Driessen, Antoine H G and Lee, Mark Y and Hoff, Steven J and Bello, David and Dunnington, Gansevoort and Eisenberg, Susan and Vloka, Margot and Taylor, Benedict J and Jones, Stephen D and Philpott, Jonathan M and Beaver, Thomas M and Miles, William M and Khan, Junaid H and Kang, Steven and Gandhi, Gaurang D and Okum, Eric J and Badhwar, Nitish and Baykaner, Tina and Lee, Anson M and Vesco, Paul A and Smith, J Michael and Gaynor, Sydney and Frazier, Ken and Lee, Randall J and Kasirajan, Vigneshwar},
title = {Dual Epicardial and Endocardial Procedure (DEEP) for Persistent or Longstanding Persistent Atrial Fibrillation},
journal = {Circulation: Arrhythmia and Electrophysiology},
year = {2025},
doi = {10.1161/circep.125.013692}
}
EUVIMED